Abbreviations: ACC, acetyl-CoA carboxylase; AMPK, AMP-activated protein kinase; IQA, isoquinoline alkaloid; RNAi, RNA interference; NHR, nuclear hormone receptor 2 Metabolic syndrome and related disorders are increasingly prevalent in contemporary society, and thus pose the need for potent agents to control lipid accumulation in the body. This study indicates that Caenorhabditis elegans was effective in screening for potent lipid metabolism modulators with berberine as a model compound. Among the various isoquinoline alkaloids tested, sanguinarine, a benzophenanthridine alkaloid, was found to be the most potent. Sanguinarine, like berberine, reduced lipid accumulation through AMP-activated protein kinase activation. Analysis of AMPK (aak-1 and aak-2) RNAi worms revealed that effects were aak-2-dependent. Characterization of worms with knockdown nhr-49, a hormone nuclear receptor gene that functions as a key regulator of fat consumption, showed that both alkaloids were effective even in these markedly lipid-accumulating nhr-49 RNAi worms, suggesting that they predominantly affect lipid synthesis, rather than fatty acid β-oxidation. The versatility of C. elegans for the purpose of lipid-modulating chemical screening and characterization of the underlying mechanisms is discussed.
Risk factors for metabolic syndrome, such as obesity, diabetes, and high blood pressure, are major concerns in modern society. To help reduce these health risks, many studies have been done to identify agents that can potently control the accumulation of lipids, which mediate metabolic syndrome. Several natural compounds, including catechin in green tea and capsaicin in chili pepper, have been reported to be good candidates. 1, 2) In this study, we screened for more potent candidates among alkaloids, which exhibit strong pharmacological activities, and particularly isoquinoline alkaloids.
Berberine, a benzylisoquinoline alkaloid that can be obtained from Berberis (Berberidaccae) and Coptis rhizomes, is used as an antibacterial agent in the treatment of gut infections and diarrhea. Recent reports on decreased plasma cholesterol and triglyceride levels in hypercholesterolemic patients, and reduced body weight and plasma triglyceride levels and improved insulin action in rats fed high-fat diets under treatment with berberine, suggest that it can be useful as a cholesterol-lowering drug.
3) Furthermore, recent advances in the metabolic engineering of isoquinoline alkaloid biosynthesis, including both synthetic biology and chemical synthesis, have indicated that it might be possible to produce a wide array of alkaloids of this type. 4, 5) In this study, we used Caenorhabditis elegans as a live model to detect the biological activities of isoquinoline alkaloids, since this worm offers several distinct advantages in preliminary screening, in terms of cost, time, and ease of manipulation, as well as effectiveness in gene-to-drug screening. 6, 7) Furthermore, an intact animal offers advantages over in vitro or cell-based assays for subsequent application to the whole animal. 8) In addition, C. elegans largely shares the core mechanisms of the regulatory pathways of mammalian energy homeostasis. The usefulness of C.
elegans in screening small molecules to identify new regulators of fat storage has been demonstrated by Lemieux et al. 9) Initially, we validated this worm bioassay system with berberine as a model modulator of lipid metabolism, and further screened several isoquinoline alkaloids for lipid metabolism-modulation activity. Among the isoquinoline alkaloids examined, sanguinarine had a greater effect on lipid accumulation than berberine.
Since there are no previous reports to the effect that sanguinarine affects lipid metabolism or the insulin signaling pathway, except for a recent report that it directly activated AMP-activated protein kinase (AMPK), 10) we examined the mechanism by which sanguinarine reduces lipid levels through the AMPK pathway, since there are various AMPK activators and AMPK activation mechanisms.
AMPK functions as a fuel gauge, as it were, in biological systems, and is a 12) was knocked down, and the effects of berberine and sanguinarine were examined.
Materials and Methods

Chemicals and reagents. Berberine sulfate was purchased from Tokyo Chemical
Industry (Tokyo, Japan); AICAR from Wako Pure Chemicals (Osaka, Japan); sanguinarine chloride, alpha lipoic acid, and cholesterol from Sigma-Aldrich Japan (Tokyo, Japan); and magnoflorine, aromoline, tetrandrine, and isotetrandrine were the kind gift of Dr. K. Iwasa (Kobe Pharmaceutical University).
Phospho-Thr172-AMPK and AMPK antibodies were from Cell Signaling Technology (Danvers, MA), and horseradish peroxide-conjugated donkey anti-rabbit IgG, from GE Healthcare Japan (Hino, Japan Procedures for immunoblot analysis are described in Supplemental Information. Differences were considered to be significant at p < 0.05. Error bars represent standard deviation unless otherwise stated.
Results and Discussion
Nile Red and Oil Red O staining revealed the effects of isoquinoline alkaloids on lipid accumulation in the treated worms
In preliminary experiments, we examined the effect of berberine, a known lipid modulator, by Nile Red staining 9, 17) and confirmed that it has a lipid-reducing effect. We further validated the effect of berberine by Oil Red O stain, since it is a more accurate proxy for major fat stores in the subcellular compartments of the worm.
14)
Next we examined the effects of several other isoquinoline alkaloids (sanguinarine, magnoflorine, isotetrandrine, tetrandrine, and aromoline), by Nile Red stain. AICAR, an AMP mimetic nucleoside commonly used to activate AMPK, and alpha lipoic acid, which improves hypertriglyceridemia by stimulating triacylglycerol clearance and downregulating liver triacylglycerol secretion, were selected as reference lipid-reducing agents. 18, 19) Treatment of worms with berberine, sanguinarine, and AICAR at 1 mM Fig. 2A and B) . All the worms showed normal growth and mobility during the 24-h treatment period.
The lipid-reducing effect of sanguinarine was further verified by Oil Red O stain ( Fig. 2C and D) . Due to the limited availability of some chemicals, we confirmed only that magnoflorine and tetrandrine did not have lipid-reducing effects by Oil Red O stain (Supplemental Fig. 2 ). Sanguinarine exhibited much stronger lipid-reducing activity than berberine. It significantly reduced lipid accumulation at a concentration (25 µM) almost 20-fold lower than the effective concentration of berberine ( Fig. 3 and Supplemental Fig. 3 ).
Sanguinarine induced phosphorylation of AMPK
The AMPK pathway has been reported to be involved in the regulation of fat metabolism for berberine-induced fat reduction, 18) in which the inhibition of ACC in HepG2 cells resulted in inhibition of cholesterol and triglyceride synthesis. 20) We further characterized the effects of sanguinarine on AMPK and its downstream molecules in comparison with the effects of berberine.
To determine the conditions for activation of AMPK, we checked its phosphorylation conditions with anti-phospho AMPK (pAMPK)-specific antibody.
Treatment with sanguinarine and AICAR induced the phosphorylation of AMPK (Fig. 4) , whereas berberine had only a marginal effect, but phosphorylation of AMPK by treatment with berberine has been reported. 20, 21) A possible explanation for the weak phosphorylation detected in our experiments is the lower reaction specificity of the antibody against C. elegans proteins, since previously we detected phosphorylation of AMPK induced by berberine in HepG2 cells (data not shown).
Knockdown of the C. elegans homologs of catalytic α-subunits of AMPK revealed elegans homologs of the catalytic α-subunits of AMPK, aak-1, and aak-2. AAK-1
and AAK-2 are 40% and 52% identical to and share 71% and 80% amino acid identity respectively with the kinase domain of human AMPKα subunits. They also contain a conserved critical threonine residue, the phosphorylation of which is required for AMPK activation.
11) The function of AAK-1 has not been much characterized, except for a study by Lemieux et al. 9) in which they identified an undisclosed compound, F17, that activated AMPK signaling in C. elegans via aak-1.
When aak-1 or aak-2 was knocked down by RNA interference (RNAi) with double-stranded RNA of these genes, lipid levels were reduced by berberine and sanguinarine in the aak-1 RNAi worms, while there was little response in the aak-2
RNAi worms ( Fig. 5A and B) , which suggests that AMPK, and especially aak-2, plays an important role in the lipid reduction induced by berberine and sanguinarine.
Quantitative real-time PCR (qRT-PCR) analysis of the transcripts of aak-1 and aak-2 in the aak-1 RNAi worms indicated that aak-2 expression was induced roughly in proportion to reduction in aak-1 (Supplemental Fig. 4A ). On the other hand, the aak-1 transcript level was unaffected in the aak-2 RNAi worms (Supplemental Fig.   4B ). These results suggest that AMPKα subunit expression in the worms was regulated mainly by aak-2, that accounts for most of the basal activity and activation by berberine and sanguinarine. Li et al. 22) have reported that the α1 and α2 isoforms of the catalytic AMPK subunits in most tissues of the ischemic rat heart can be differentially activated due to different sensitivities to small changes in the AMP concentration. Our results suggest that in this worm, the aak-1 isoform of the AMPKα subunit is less responsive to activation by berberine and sanguinarine. We conducted an RNAi experiment on nhr-49 and investigated the involvement of β-oxidation in lipid-reduction by berberine and sanguinarine.
Consistently with the reported high-fat phenotype, the nhr-49i worms showed increased fat storage under Oil Red O staining ( Fig. 6A and B, Supplemental Fig. 5 ).
They showed a marked increase in body size and significantly lower expression of mitochondrial β-oxidation genes, ech-1 (encodes a mitochondrial β-oxidation trifunctional enzyme), cpt-5 (encodes a carnitine palmitoyl transferase), and acs-2
(encodes a mitochondrial acyl-CoA synthetase) (Fig. 6C) . NHRs respond to lipophilic molecules, regulating the expression of target genes involved in metabolism, reproduction, and development. 17) Liang et al. 23) have reported that NHR-64, another C. elegans HNF4 nuclear receptor, regulates fat storage, growth, and brood size in these worms.
Despite their high fat accumulation, the nhr-49 knockdown worms were sensitive to berberine and sanguinarine, suggesting that both alkaloids act independently of nhr-49 (Fig. 6A) . Unexpectedly, an analysis of nhr-49 transcript levels in RNAi control worms (pL4440) treated with berberine and sanguinarine showed reduced nhr-49 expression (Fig. 6D ), albeit to a lesser extent than for nhr-49
RNAi. While the details of the antagonistic action of berberine and sanguinarine on 
Effects of plant alkaloids on lipid modulation and the mechanisms
In our primary screening of isoquinoline alkaloids, protoberberine (berberine)-and benzophenanthridine (sanguinarine)-type compounds showed lipid-reducing activity, while other types of isoquinoline alkaloids, including aporphine Plant alkaloids perhaps defend against herbivores and pathogens. Many alkaloids have been reported to be mitochondrial inhibitors and might also be potent AMPK activators. 27) Activation of AMPK by berberine and sanguinarine might be the result of inhibition of ATP synthesis and an increase in the AMP level based on the finding that these alkaloids inhibited mitochondrial respiration. 21) Studies of cell lines that express AMPK complexes bearing an R531G mutation, which renders γ2 complexes insensitive to increases in ADP and AMP, have indicated that berberine works by increasing cellular AMP or ADP. On the other hand, Choi et al. 10) reported that sanguinarine directly interacted with AMPK and enhanced its activity to a level above that mediated by AMP.
It would be interesting to investigate the difference between indirect and direct AMPK activation and its implications for the potency of alkaloid bioactivity.
Although both berberine and sanguinarine activate AMPK, the difference in the uptake efficiency of these chemicals should also be considered, since Turner et al. 21) have reported greater absorption of dihydroberberine as compared to berberine due to the structural modification.
Besides reductions in lipid synthesis, increments in lipid consumption might also decrease lipid accumulation in an organism. We investigated this with nhr-49 knockdown worms. Our nhr-49 RNAi experiment showed reduced lipid accumulation under berberine and sanguinarine treatment (Fig. 6A) , while nhr-49 expression was also reduced in the control worms treated with both alkaloids (Fig.   6D ). NHR-49 acts as a positive regulator of acs-2 and ech-1 promoting fatty acid oxidation by mitochondria. Pathare et al. 28) have reported that NHR-49 activated and repressed genes in multiple lipid metabolism pathways. Thus knockdown of nhr-49 can lead to high lipid accumulation ( Fig. 6A and B) . Our results suggest that berberine and sanguinarine have antagonistic actions on and lipid synthesis (via AMPK activation) and oxidation (via NHR-49 downregulation) processes. The stronger effects of sanguinarine and berberine treatment in lipid reduction suggest that lipid biosynthesis regulated by AMPK activation predominates over the downregulated lipid degradation process due to nhr-49 (Supplemental Fig. 1) .
Versatility of the worm
The results of this study confirm the feasibility of using C. elegans for bioactivity screening of plant isoquinoline alkaloids. One of the advantages of C.
elegans is that about 40% of the genes associated with human therapeutical targets have homologs in the worm, which makes it a good model for studying drug-target interaction and target validation. This worm has been instrumental in elucidating important aspects of several important receptor-based pathways that regulate energy storage and utilization, including insulin, serotonin, TGF-β, and adiponectin. 29) We have used a combination of genetic and biochemical approaches to characterize the lipid metabolism modulation effects of plant alkaloids. In this study, we confirmed that the lipid-reducing activity of sanguinarine is linked to the AMPK signaling pathway and not dependent on the NHR-49 pathway, similarly to berberine (Figs. 4-6) . Whereas most previous studies of AMPK activation used liver cells of rodents or another mammalian model, our study indicates that C. elegans can also be used. These findings are advantageous for bioactivity screening, since they expand the scope of the worm in multiple assays beyond preliminary screening. Promising candidate compounds can be later validated in mammalian models, and this might ultimately reduce the overall cost of drug development.
Although C. elegans can serve well as a screening model, the effective concentration of berberine (400 µM) in this worm to reduce lipid accumulation was much higher than the effective concentration (7 µM) reported for a human hepatoma-derived cell, the HepG2 cell. 3) This difference might be due to the potential difference in the target sites, and also to different absorption and/or degradation ability of those cells for berberine. Sanguinarine showed higher lipid reducing activity than berberine at low concentrations such as 25 µM (Fig. 3 ). This concentration is very close to the EC 50 value (26 to 28 µM) that activated human recombinant AMPK in an in vitro assay. 10) Our preliminary experiments with the nhr-8 RNAi worm with a knocked-down xenobiotic response, which showed enhanced sensitivity to berberine, may provide clues to understanding the differences between the uptake and metabolism of berberine and sanguinarine in vivo (Chow and Sato, in preparation).
Moreover, screening in an intact worm makes it possible simultaneously to monitor toxicity, which is not possible in an in vitro assay. For instance, besides lipid-reducing effects, berberine and sanguinarine also have cytotoxic activity, similarly to many plant alkaloids. These chemicals were known to form complexes with DNA and RNA, and to inhibit telomerase and topoisomerase. 30) Sanguinarine exhibited both stronger lipid-reducing activity and stronger cytotoxicity (Supplemental Fig. 6 ). Separation of the cytotoxic effects from the desired lipid-reducing activity for sanguinarine and related alkaloids is crucial for therapeutical applications.
In this study, we screened for bioactivities in pure, isolated compounds. As has been demonstrated in most ethnobotanical or traditional medicine applications, therapeutic effects are often produced by a concoction of plant extracts. Our future studies will incorporate extracts from medicinal plant cells, including metabolically engineered plant cell cultures, to screen for synergistic bioactivities among plant alkaloids. 
Figure legends
